Lee S T, Amin M J
Ear, Nose, Throat and Allergy Clinic, Mt Elizabeth Medical Centre, Singapore.
Singapore Med J. 1994 Dec;35(6):591-4.
Nonsedating selective peripheral H1 receptor antagonists are an important advance in antihistaminic therapy in allergic patients. This is a randomised, double-blind parallel group study comparing the use of two such agents viz loratadine 10mg daily and astemizole 10mg daily for two weeks in 39 Malaysian allergic rhinitis patients. At these dosages, both drugs were demonstrated to be efficacious (p < 0.05) for controlling nasal symptoms and safe in terms of short term biochemical and haematological changes and adverse effects noted. Evaluating efficacy criteria utilised in this study loratadine and astemizole were comparable but loratadine was significantly more effective in three areas viz: (i) in diminishing nasal symptoms after 2 weeks of treatment (p = 0.03); (ii) physician's efficacy evaluation after 2 weeks' treatment (p = 0.009); (iii) patient's efficacy evaluation after 2 weeks' treatment (p = 0.019).
非镇静性选择性外周H1受体拮抗剂是变应性疾病患者抗组胺治疗的一项重要进展。这是一项随机、双盲平行组研究，比较了两种此类药物，即每日10毫克氯雷他定和每日10毫克阿司咪唑，在39名马来西亚变应性鼻炎患者中使用两周的情况。在这些剂量下，两种药物在控制鼻部症状方面均显示有效（p<0.05），就短期生化和血液学变化以及所观察到的不良反应而言是安全的。根据本研究中使用的疗效评估标准，氯雷他定和阿司咪唑具有可比性，但氯雷他定在三个方面明显更有效，即：（i）治疗2周后减轻鼻部症状（p=0.03）；（ii）治疗2周后医生的疗效评估（p=0.009）；（iii）治疗2周后患者的疗效评估（p=0.019）。
